Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: PerkinElmer, Qiagen, Inivata, and More

NEW YORK (GenomeWeb) – PerkinElmer this week declared a regular quarterly dividend of $.07 per share of common stock, payable on Feb. 9 to all shareholders of record at the close of business on Jan. 19, 2018.

Qiagen this week launched a custom solutions business to provide life sciences and molecular diagnostics companies with tools and expertise to quickly build and commercialize products. The new business will offer custom and OEM sample technologies; oligos and enzymes for PCR, qPCR, and next-generation sequencing product development; and a broad range of other platform technologies. Qiagen noted that approximately 10 percent of its sales have been reinvested in R&D to help support the new business.

Inivata announced this week that the West Cancer Center will join the Inivata Knowledge Accumulation Network (IKAN). The IKAN is a global network of leading cancer centers working in partnership with Inivata to assess the potential of liquid biopsy to improve patient outcomes.

UK-based liquid biopsy firm Angle said this week that it has completed a fundraising, and acquisition of certain assets of microarray firm Axela. In October, Angle said that it intended to acquire intellectual property, fixed assets, inventory, employees, a property leasehold interest, and other of Axela's assets for a total of £3.7 million ($4.9 million). To fund the acquisition, the company proposed a placing of shares and subscriptions that would raise approximately £12.2 million before expenses.

Almac said this week that it has acquired all shares of BioClin Laboratories, an Ireland-based organization providing analytical services, including GMP microbiology testing and GLP bioanalysis. Terms of the transaction were not disclosed. The deal expands Almac’s analytical capacity and complements its existing business, the firm said, adding that it recently completed an expansion of its analytical facilities at its global headquarters site in Northern Ireland, with the creation of a new MHRA-approved laboratory.

Singulex this week filed a 510(k) submission with the US Food and Drug Administration for its Singulex Clarity cTnl assay to run on the Singulex Clarity system. The fully automated in vitro diagnostics platform leverages Singulex's Single Molecule Counting technology, and the assay quantitatively measures cardiac troponin at levers “far lower than existing technologies,” the company said. It added that the indication submitted to the FDA is for use in conjunction with clinical evaluation as an aid in the diagnosis of myocardial infarction.

Genohm announced this week that it has successfully achieved ISO 9001:2015 certification. ISO 9001 is an internationally recognized standard that specifies the requirements for a quality management system. Genohm's ISO 9001:2015 certification demonstrates a commitment to maintaining the highest QMS level throughout the company, the firm said.

Co-Diagnostics this week was granted ISO 13485:2016 certification following an audit of its quality management system, done by DQS in August. The company’s certificate is valid until September 2020. The scope of the certificate includes the design and manufacture of medical products for handling, stabilizing, separating, purifying, amplifying, and detecting nucleic acids, the firm said.

Evogene announced this week that it has revised and expanded its market areas of focus, including agriculture, and established a new corporate structure. Under the new structure, the enhancement, operation, and maintenance of the company's computational predictive biology platform will continue to be led by Yuval Ben-Galim, Evogene's executive vice president of technology and operations (and former chief operating officer). Evogene's discovery and product development programs in the field of agriculture will be split into three operating divisions: Ag-biologicals, for the development of microbial-based yield improvement and pest control products; Ag-chemicals, for the development of novel herbicides and insecticides; and Ag-seeds, for the development of improved seed traits, yield increase, drought tolerance, insect control, and disease resistance, through the use of genome editing and gene transformation.

Proteome Sciences announced this week that it has received Good Clinical Laboratory Practice accreditation, which will enable the company to use its proteomic services to analyze clinical trial samples. Proteome Sciences is a contract research organization offering various discovery services to characterize proteins and their associated post translational modifications.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.